SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number 000-22052
(Check one)
[X] Form 10-K and Form 10-KSB [ ] Form 11-K
[ ]Form 20-F [ ] Form 10-Q and Form 10-QSB [ ] Form N-SAR
For period ended December 31, 2002
------------------------------------------------------
[ ] Transition Report on Form 10-K and Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q and Form 10-QSB
[ ] Transition Report on Form N-SAR
For the transition period ended
---------------------------------------
READ ATTACHED INSTRUCTION SHEET BEFORE PREPARING FORM. PLEASE PRINT OR TYPE.
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
PART I
REGISTRANT INFORMATION
Full name of registrant ProxyMed, Inc.
-----------------------------------------------
Former name if applicable
---------------------------------------------
2555 Davie Road, Suite 110
--------------------------------------------------------------------------------
Address of principal executive office (Street and number)
Fort Lauderdale, Florida 33117
--------------------------------------------------------------------------------
City, state and zip code
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or
portion thereof will be filed on or before the 15th calendar
day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, 10-QSB, or
portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 10-KSB,
11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report portion thereof could
not be filed within the prescribed time period. (Attach extra sheets if needed.)
On December 31, 2002, ProxyMed, Inc. ("ProxyMed" or the "Company")
acquired 100% of the capital stock of MedUnite, Inc., a leading provider of
healthcare claims processing services, founded by seven of the nation's largest
health insurers ("MedUnite"). The Company recently completed an audit of
MedUnite's financials for 2002 and is currently in the process of integrating
MedUnite's customers and technology into ProxyMed's operations, including the
migration of customers from MedUnite's claims processing platform to ProxyMed's
healthcare information network. In addition, the Company is moving to
consolidate its facilities and workforce with those of MedUnite. As a result,
the Company has been unable to complete and file its Form 10-K within the
prescribed deadline and otherwise in accordance with applicable SEC rules and
regulations without, among other things, unreasonable effort and expense.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Judson E. Schmid 954 473-1001
--------------------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) or
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report(s) been
filed? If the answer is no, identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
[ ] Yes [X] No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
ProxyMed, Inc. has caused this notification to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: March 28, 2002 By: /s/ Judson E. Schmid
--------------------------------------
Judson E. Schmid, Chief Financial Officer